Nonsense-mediated decay in genetic disease: Friend or foe?

Mutation Research - Reviews in Mutation Research

Volumn 762, Issue , 2014, Pages 52-64

  Miller, Jake N ^a,b   Pearce, David A ^a,b  

^a UNIVERSITY OF SOUTH DAKOTA   (United States)

^b SANFORD RESEARCH   (United States)

Author keywords

Genetic disease; Nonsense suppression; Nonsense mediated decay; Read through

Indexed keywords

CELL SPECIFICITY; GENE EXPRESSION; GENE REPRESSION; GENETIC DISORDER; GENETIC VARIABILITY; HUMAN; INHERITANCE; MOLECULAR RECOGNITION; NONHUMAN; NONSENSE MEDIATED MRNA DECAY; NONSENSE MUTATION; PHENOTYPE; REGULATORY MECHANISM; REVIEW; RNA DEGRADATION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE SPECIFICITY; ANIMAL; ANTIBODY SPECIFICITY; CLASSIFICATION; DISEASES; GENE EXPRESSION REGULATION; GENETICS; METABOLISM;

EUKARYOTA;

MESSENGER RNA;

ANIMALS; DISEASE; GENE EXPRESSION REGULATION; HUMANS; NONSENSE MEDIATED MRNA DECAY; ORGAN SPECIFICITY; RNA, MESSENGER;

EID: 84919687395     PISSN: 13835742     EISSN: 13882139     Source Type: Journal    
DOI: 10.1016/j.mrrev.2014.05.001     Document Type: Review

References (173)

1. Keeling K.M., Bedwell D.M. Suppression of nonsense mutations as a therapeutic approach to treat genetic diseases. Wiley Interdiscip. Rev. RNA 2011, 2:837-852.
2. Frischmeyer P.A., Dietz H.C. Nonsense-mediated mRNA decay in health and disease. Hum. Mol. Genet. 1999, 8:1893-1900.
3. Krawczak M., Ball E.V., Cooper D.N. Neighboring-nucleotide effects on the rates of germ-line single-base-pair substitution in human genes. Am. J. Hum. Genet. 1998, 63:474-488.
4. Mort M., et al. A meta-analysis of nonsense mutations causing human genetic disease. Hum. Mutat. 2008, 29:1037-1047.
5. Chang Y.F., Imam J.S., Wilkinson M.F. The nonsense-mediated decay RNA surveillance pathway. Annu. Rev. Biochem. 2007, 76:51-74.
6. Kervestin S., Jacobson A. NMD: a multifaceted response to premature translational termination. Nat. Rev. Mol. Cell Biol. 2012, 13:700-712.
7. Schoenberg D.R., Maquat L.E. Regulation of cytoplasmic mRNA decay. Nat. Rev. Genet. 2012, 13:246-259.
8. Balagopal V., Fluch L., Nissan T. Ways and means of eukaryotic mRNA decay. Biochim. Biophys. Acta 2012, 1819:593-603.
9. Muhlemann O., et al. Recognition and elimination of nonsense mRNA. Biochim. Biophys. Acta 2008, 1779:538-549.
10. Khajavi M., Inoue K., Lupski J.R. Nonsense-mediated mRNA decay modulates clinical outcome of genetic disease. Eur. J. Hum. Genet. 2006, 14:1074-1081.
11. Holbrook J.A., et al. Nonsense-mediated decay approaches the clinic. Nat. Genet. 2004, 36:801-808.
12. Bashyam M.D. Nonsense-mediated decay: linking a basic cellular process to human disease. Expert Rev. Mol. Diagn. 2009, 9:299-303.
13. Doma M.K., Parker R. RNA quality control in eukaryotes. Cell 2007, 131:660-668.
14. Grzybowska E.A. Human intronless genes: functional groups, associated diseases, evolution, and mRNA processing in absence of splicing. Biochem. Biophys. Res. Commun. 2012, 424:1-6.
15. Lee H.C., et al. Nonsense-mediated translational repression involves exon junction complex downstream of premature translation termination codon. FEBS Lett. 2010, 584:795-800.
16. Maquat L.E., Tarn W.Y., Isken O. The pioneer round of translation: features and functions. Cell 2010, 142:368-374.
17. Maniatis T., Reed R. An extensive network of coupling among gene expression machines. Nature 2002, 416:499-506.
18. Moore M.J., Proudfoot N.J. Pre-mRNA processing reaches back to transcription and ahead to translation. Cell 2009, 136:688-700.
19. Brocke K.S., et al. The human intronless melanocortin 4-receptor gene is NMD insensitive. Hum. Mol. Genet. 2002, 11:331-335.
20. Maquat L.E., Li X. Mammalian heat shock p70 and histone H4 transcripts, which derive from naturally intronless genes, are immune to nonsense-mediated decay. RNA 2001, 7:445-456.
21. Chan W.K., et al. An alternative branch of the nonsense-mediated decay pathway. EMBO J. 2007, 26:1820-1830.
22. Chan W.K., et al. A UPF3-mediated regulatory switch that maintains RNA surveillance. Nat. Struct. Mol. Biol. 2009, 16:747-753.
23. Huang L., Wilkinson M.F. Regulation of nonsense-mediated mRNA decay. Wiley Interdiscip. Rev. RNA 2012, 3:807-828.
24. Kim Y.K., et al. Mammalian Staufen1 recruits Upf1 to specific mRNA 3'UTRs so as to elicit mRNA decay. Cell 2005, 120:195-208.
25. Nagy E., Maquat L.E. A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance. Trends Biochem. Sci. 1998, 23:198-199.
26. Houseley J., LaCava J., Tollervey D. RNA-quality control by the exosome. Nat. Rev. Mol. Cell Biol. 2006, 7:529-539.
27. Franks T.M., Singh G., Lykke-Andersen J. Upf1 ATPase-dependent mRNP disassembly is required for completion of nonsense-mediated mRNA decay. Cell 2010, 143:938-950.
28. Mendell J.T., et al. Nonsense surveillance regulates expression of diverse classes of mammalian transcripts and mutes genomic noise. Nat. Genet. 2004, 36:1073-1078.
29. Wilkinson M.F. A new function for nonsense-mediated mRNA-decay factors. Trends Genet. 2005, 21:143-148.
30. Lejeune F., Maquat L.E. Mechanistic links between nonsense-mediated mRNA decay and pre-mRNA splicing in mammalian cells. Curr. Opin. Cell Biol. 2005, 17:309-315.
31. Weischenfeldt J., et al. Mammalian tissues defective in nonsense-mediated mRNA decay display highly aberrant splicing patterns. Genome Biol. 2012, 13:R35.
32. Sharifi N.A., Dietz H.C. Physiologic Substrates and Functions for Mammalian NMD. In Nonsense-Mediated mRNA Decay 2006, Landes Bioscience, Austin, TX.
33. Gardner L.B. Hypoxic inhibition of nonsense-mediated RNA decay regulates gene expression and the integrated stress response. Mol. Cell Biol. 2008, 28:3729-3741.
34. Gardner L.B., Corn P.G. Hypoxic regulation of mRNA expression. Cell Cycle 2008, 7:1916-1924.
35. Tarpey P.S., et al. Mutations in UPF3B, a member of the nonsense-mediated mRNA decay complex, cause syndromic and nonsyndromic mental retardation. Nat. Genet. 2007, 39:1127-1133.
36. Nguyen L.S., et al. Contribution of copy number variants involving nonsense-mediated mRNA decay pathway genes to neuro-developmental disorders. Hum. Mol. Genet. 2013, 22:1816-1825.
37. Hwang J., Maquat L.E. Nonsense-mediated mRNA decay (NMD) in animal embryogenesis: to die or not to die, that is the question. Curr. Opin. Genet. Dev. 2011, 21:422-430.
38. Bateman J.F., et al. Tissue-specific RNA surveillance? Nonsense-mediated mRNA decay causes collagen X haploinsufficiency in Schmid metaphyseal chondrodysplasia cartilage. Hum. Mol. Genet. 2003, 12:217-225.
39. Zetoune A.B., et al. Comparison of nonsense-mediated mRNA decay efficiency in various murine tissues. BMC Genet. 2008, 9:83.
40. Hwang J., et al. UPF1 association with the cap-binding protein, CBP80, promotes nonsense-mediated mRNA decay at two distinct steps. Mol. Cell 2010, 39:396-409.
41. Isken O., et al. Upf1 phosphorylation triggers translational repression during nonsense-mediated mRNA decay. Cell 2008, 133:314-327.
42. Okada-Katsuhata Y., et al. N- and C-terminal Upf1 phosphorylations create binding platforms for SMG-6 and SMG-5: SMG-7 during NMD. Nucl. Acids Res. 2012, 40:1251-1266.
43. Kashima I., et al. Binding of a novel SMG-1-Upf1-eRF1-eRF3 complex (SURF) to the exon junction complex triggers Upf1 phosphorylation and nonsense-mediated mRNA decay. Genes Dev. 2006, 20:355-367.
44. Ohnishi T., et al. Phosphorylation of hUPF1 induces formation of mRNA surveillance complexes containing hSMG-5 and hSMG-7. Mol. Cell 2003, 12:1187-1200.
45. Huang L., et al. RNA homeostasis governed by cell type-specific and branched feedback loops acting on NMD. Mol. Cell 2011, 43:950-961.
46. Yepiskoposyan H., et al. Autoregulation of the nonsense-mediated mRNA decay pathway in human cells. RNA 2011, 17:2108-2118.
47. Bruno I.G., et al. Identification of a microRNA that activates gene expression by repressing nonsense-mediated RNA decay. Mol. Cell 2011, 42:500-510.
48. Lee R.C., Feinbaum R.L., Ambros V. The C elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14. Cell 1993, 75:843-854.
49. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
50. Bartel D.P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
51. Bartel D.P. MicroRNAs: target recognition and regulatory functions. Cell 2009, 136:215-233.
52. Baek D., et al. The impact of microRNAs on protein output. Nature 2008, 455:64-71.
53. Selbach M., et al. Widespread changes in protein synthesis induced by microRNAs. Nature 2008, 455:58-63.
54. Karam R., Wilkinson M. A conserved microRNA/NMD regulatory circuit controls gene expression. RNA Biol. 2012, 9:22-26.
55. Abu-Elneel K., et al. Heterogeneous dysregulation of microRNAs across the autism spectrum. Neurogenetics 2008, 9:153-161.
56. Saba R., et al. A miRNA signature of prion induced neurodegeneration. PLoS ONE 2008, 3:e3652.
57. Lee S.T., et al. Altered microRNA regulation in Huntington's disease models. Exp. Neurol. 2011, 227:172-179.
58. Kim J., et al. A MicroRNA feedback circuit in midbrain dopamine neurons. Science 2007, 317:1220-1224.
59. Lukiw W.J. Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus. Neuroreport 2007, 18:297-300.
60. Carter M.S., Li S., Wilkinson M.F. A splicing-dependent regulatory mechanism that detects translation signals. EMBO J. 1996, 15:5965-5975.
61. Frischmeyer-Guerrerio P.A., et al. Perturbation of thymocyte development in nonsense-mediated decay (NMD)-deficient mice. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:10638-10643.
62. Tan J.T., et al. Competency for nonsense-mediated reduction in collagen X mRNA is specified by the 3' UTR and corresponds to the position of mutations in Schmid metaphyseal chondrodysplasia. Am. J. Hum. Genet. 2008, 82:786-793.
63. Resta N., et al. A homozygous frameshift mutation in the ESCO2 gene: evidence of intertissue and interindividual variation in Nmd efficiency. J. Cell Physiol. 2006, 209:67-73.
64. Kebaara B., et al. Genetic background affects relative nonsense mRNA accumulation in wild-type and upf mutant yeast strains. Curr. Genet. 2003, 43:171-177.
65. Linde L., et al. The efficiency of nonsense-mediated mRNA decay is an inherent character and varies among different cells. Eur. J. Hum. Genet. 2007, 15:1156-1162.
66. Perrin-Vidoz L., et al. The nonsense-mediated mRNA decay pathway triggers degradation of most BRCA1 mRNAs bearing premature termination codons. Hum. Mol. Genet. 2002, 11:2805-2814.
67. Linde L., et al. Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J. Clin. Invest. 2007, 117:683-692.
68. Viegas M.H., et al. The abundance of RNPS1, a protein component of the exon junction complex, can determine the variability in efficiency of the nonsense mediated decay pathway. Nucl. Acids Res. 2007, 35:4542-4551.
69. Usuki F., et al. Specific inhibition of nonsense-mediated mRNA decay components, SMG-1 or Upf1, rescues the phenotype of Ullrich disease fibroblasts. Mol. Ther. 2006, 14:351-360.
70. Geiger S.K., et al. Incomplete nonsense-mediated decay of mutant lamin A/C mRNA provokes dilated cardiomyopathy and ventricular tachycardia. J. Mol. Med. (Berl) 2008, 86:281-289.
71. Seoighe C., Gehring C. Heritability in the efficiency of nonsense-mediated mRNA decay in humans. PLoS ONE 2010, 5:e11657.
72. Hall G.W., Thein S. Nonsense codon mutations in the terminal exon of the beta-globin gene are not associated with a reduction in beta-mRNA accumulation: a mechanism for the phenotype of dominant beta-thalassemia. Blood 1994, 83:2031-2037.
73. Thein S.L., et al. Molecular basis for dominantly inherited inclusion body beta-thalassemia. Proc. Natl. Acad. Sci. U.S.A. 1990, 87:3924-3928.
74. Baserga S.J., Benz E.J. Nonsense mutations in the human beta-globin gene affect mRNA metabolism. Proc. Natl. Acad. Sci. U.S.A. 1988, 85:2056-2060.
75. Forget B.G., et al. Absence of messenger RNA for beta globin chain in beta(0) thalassaemia. Nature 1974, 247:379-381.
76. Jouanguy E., et al. Interferon-gamma-receptor deficiency in an infant with fatal bacille Calmette-Guerin infection. N. Engl. J. Med. 1996, 335:1956-1961.
77. Jouanguy E., et al. A human IFNGR1 small deletion hotspot associated with dominant susceptibility to mycobacterial infection. Nat. Genet. 1999, 21:370-378.
78. Schwabe G.C., et al. Distinct mutations in the receptor tyrosine kinase gene ROR2 cause brachydactyly type B. Am. J. Hum. Genet. 2000, 67:822-831.
79. Patton M.A., Afzal A.R. Robinow syndrome. J. Med. Genet. 2002, 39:305-310.
80. Schneppenheim R., et al. Expression and characterization of von Willebrand factor dimerization defects in different types of von Willebrand disease. Blood 2001, 97:2059-2066.
81. Millar D.S., et al. Molecular analysis of the genotype-phenotype relationship in factor X deficiency. Hum. Genet. 2000, 106:249-257.
82. Rosenfeld P.J., et al. A null mutation in the rhodopsin gene causes rod photoreceptor dysfunction and autosomal recessive retinitis pigmentosa. Nat. Genet. 1992, 1:209-213.
83. Sung C.H., et al. Rhodopsin mutations in autosomal dominant retinitis pigmentosa. Proc. Natl. Acad. Sci. U.S.A. 1991, 88:6481-6485.
84. Pusch M. Myotonia caused by mutations in the muscle chloride channel gene CLCN1. Hum. Mutat. 2002, 19:423-434.
85. Rivolta C., Berson E.L., Dryja T.P. Dominant Leber congenital amaurosis, cone-rod degeneration, and retinitis pigmentosa caused by mutant versions of the transcription factor CRX. Hum. Mutat. 2001, 18:488-498.
86. Plomp A.S., et al. Does autosomal dominant pseudoxanthoma elasticum exist?. Am. J. Med. Genet. A 2004, 126A:403-412.
87. Inoue K., et al. Molecular mechanism for distinct neurological phenotypes conveyed by allelic truncating mutations. Nat. Genet. 2004, 36:361-369.
88. Inoue K., et al. Translation of SOX10 3' untranslated region causes a complex severe neurocristopathy by generation of a deleterious functional domain. Hum. Mol. Genet. 2007, 16:3037-3046.
89. Warner L.E., et al. Clinical phenotypes of different MPZ (P0) mutations may include Charcot-Marie-tooth type 1B, Dejerine-Sottas, and congenital hypomyelination. Neuron 1996, 17:451-460.
90. Tassabehji M., et al. Elastin: genomic structure and point mutations in patients with supravalvular aortic stenosis. Hum. Mol. Genet. 1997, 6:1029-1036.
91. Schwarze U., et al. Rare autosomal recessive cardiac valvular form of Ehlers-Danlos syndrome results from mutations in the COL1A2 gene that activate the nonsense-mediated RNA decay pathway. Am. J. Hum. Genet. 2004, 74:917-930.
92. Plaisier E., et al. COL4A1 mutations and hereditary angiopathy, nephropathy, aneurysms, and muscle cramps. N. Engl. J. Med. 2007, 357:2687-2695.
93. Lemmens R., et al. Novel COL4A1 mutations cause cerebral small vessel disease by haploinsufficiency. Hum. Mol. Genet. 2013, 22:391-397.
94. Petruzzella V., et al. Mutations in the NDUFS4 gene of mitochondrial complex I alter stability of the splice variants. FEBS Lett. 2005, 579:3770-3776.
95. Jenkins P.B., et al. A nonsense mutation in the erythrocyte band 3 gene associated with decreased mRNA accumulation in a kindred with dominant hereditary spherocytosis. J. Clin. Invest. 1996, 97:373-380.
96. Toye A.M., et al. Band 3 Walton, a C-terminal deletion associated with distal renal tubular acidosis, is expressed in the red cell membrane but retained internally in kidney cells. Blood 2002, 99:342-347.
97. Yang Y., et al. The gene encoding alsin, a protein with three guanine-nucleotide exchange factor domains, is mutated in a form of recessive amyotrophic lateral sclerosis. Nat. Genet. 2001, 29:160-165.
98. Gros-Louis F., et al. An ALS2 gene mutation causes hereditary spastic paraplegia in a Pakistani kindred. Ann. Neurol. 2003, 53:144-145.
99. Johnston J.J., et al. Molecular and clinical analyses of Greig cephalopolysyndactyly and Pallister-Hall syndromes: robust phenotype prediction from the type and position of GLI3 mutations. Am. J. Hum. Genet. 2005, 76:609-622.
100. Furniss D., et al. Nonsense-mediated decay and the molecular pathogenesis of mutations in SALL1 and GLI3. Am. J. Med. Genet. A 2007, 143A:3150-3160.
101. Korkko J., et al. Analysis of the COL1A1 and COL1A2 genes by PCR amplification and scanning by conformation-sensitive gel electrophoresis identifies only COL1A1 mutations in 15 patients with osteogenesis imperfecta type I: identification of common sequences of null-allele mutations. Am. J. Hum. Genet. 1998, 62:98-110.
102. Willing M.C., et al. Premature chain termination is a unifying mechanism for COL1A1 null alleles in osteogenesis imperfecta type I cell strains. Am. J. Hum. Genet. 1996, 59:799-809.
103. Snead M.P., Yates J.R. Clinical and molecular genetics of Stickler syndrome. J. Med. Genet. 1999, 36:353-359.
104. Kerr T.P., et al. Long mutant dystrophins and variable phenotypes: evasion of nonsense-mediated decay?. Hum. Genet. 2001, 109:402-407.
105. Pillers D.A., et al. Duchenne/Becker muscular dystrophy: correlation of phenotype by electroretinography with sites of dystrophin mutations. Hum. Genet. 1999, 105:2-9.
106. Schrijver I., et al. Premature termination mutations in FBN1: distinct effects on differential allelic expression and on protein and clinical phenotypes. Am. J. Hum. Genet. 2002, 71:223-237.
107. Faivre L., et al. Effect of mutation type and location on clinical outcome in 1,013 probands with Marfan syndrome or related phenotypes and FBN1 mutations: an international study. Am. J. Hum. Genet. 2007, 81:454-466.
108. Gorbenko Del Blanco D., et al. Growth hormone insensitivity syndrome caused by a heterozygous GHR mutation: phenotypic variability owing to moderation by nonsense-mediated decay. Clin. Endocrinol. (Oxf) 2012, 76:706-712.
109. Houlden H., et al. A novel Frabin (FGD4) nonsense mutation p.R275X associated with phenotypic variability in CMT4H. Neurology 2009, 72:617-620.
110. Stendel C., et al. Peripheral nerve demyelination caused by a mutant Rho GTPase guanine nucleotide exchange factor, frabin/FGD4. Am. J. Hum. Genet. 2007, 81:158-164.
111. Myerowitz R. Tay-Sachs disease-causing mutations and neutral polymorphisms in the Hex A gene. Hum. Mutat. 1997, 9:195-208.
112. Alonso J., et al. Spectrum of germline RB1 gene mutations in Spanish retinoblastoma patients: phenotypic and molecular epidemiological implications. Hum. Mutat. 2001, 17:412-422.
113. Li A., Swift M. Mutations at the ataxia-telangiectasia locus and clinical phenotypes of A-T patients. Am. J. Med. Genet. 2000, 92:170-177.
114. Miller J.N., Chan C.H., Pearce D.A. The role of nonsense-mediated decay in neuronal ceroid lipofuscinosis. Hum. Mol. Genet. 2013, 22:2723-2734.
115. Drack A.V., Miller J.N., Pearce D.A. A Novel c.1135_1138delCTGT Mutation in CLN3 Leads to Juvenile Neuronal Ceroid Lipofuscinosis. J. Child Neurol. 2013.
116. Miller J.N., Pearce D.A. A Novel c.776_777insA Mutation in CLN1 Leads to Infantile Neuronal Ceroid Lipofuscinosis. J. Child Neurol. 2013.
117. Jackson R.J., Hellen C.U., Pestova T.V. Termination and post-termination events in eukaryotic translation. Adv. Protein Chem. Struct. Biol. 2012, 86:45-93.
118. Keeling K.M., et al. Suppression of premature termination codons as a therapeutic approach. Crit. Rev. Biochem. Mol. Biol. 2012, 47:444-463.
119. Lee H.L., Dougherty J.P. Pharmaceutical therapies to recode nonsense mutations in inherited diseases. Pharmacol. Ther. 2012, 136:227-266.
120. Howard M., Frizzell R.A., Bedwell D.M. Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat. Med. 1996, 2:467-469.
121. Bedwell D.M., et al. Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat. Med. 1997, 3:1280-1284.
122. Clancy J.P., et al. Evidence that systemic gentamicin suppresses premature stop mutations in patients with cystic fibrosis. Am. J. Respir. Crit. Care Med. 2001, 163:1683-1692.
123. Zsembery A., et al. Correction of CFTR malfunction and stimulation of Ca-activated Cl channels restore HCO3-secretion in cystic fibrosis bile ductular cells. Hepatology 2002, 35:95-104.
124. Rowe S.M., et al. Restoration of W1282X CFTR activity by enhanced expression. Am. J. Respir. Cell Mol. Biol. 2007, 37:347-356.
125. Du M., et al. Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTR-G542X transgene. J. Mol. Med. (Berl) 2002, 80:595-604.
126. Du M., et al. Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model. J. Mol. Med. (Berl) 2006, 84:573-582.
127. Du M., et al. PTC124 is an orally bioavailable compound that promotes suppression of the human CFTR-G542X nonsense allele in a CF mouse model. Proc. Natl. Acad. Sci. U.S.A. 2008, 105:2064-2069.
128. Nudelman I., et al. Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J. Med. Chem. 2009, 52:2836-2845.
129. Nudelman I., et al. Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg. Med. Chem. 2010, 18:3735-3746.
130. Sermet-Gaudelus I., et al. Ataluren (PTC124) induces cystic fibrosis transmembrane conductance regulator protein expression and activity in children with nonsense mutation cystic fibrosis. Am. J. Respir. Crit. Care Med. 2010, 182:1262-1272.
131. Rowe S.M., et al. Suppression of CFTR premature termination codons and rescue of CFTR protein and function by the synthetic aminoglycoside NB54. J. Mol. Med. (Berl) 2011, 89:1149-1161.
132. Barton-Davis E.R., et al. Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J. Clin. Invest. 1999, 104:375-381.
133. Howard M.T., et al. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann. Neurol. 2000, 48:164-169.
134. Bidou L., et al. Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment. Gene Ther. 2004, 11:619-627.
135. Howard M.T., et al. Readthrough of dystrophin stop codon mutations induced by aminoglycosides. Ann. Neurol. 2004, 55:422-426.
136. Loufrani L., et al. Absence of dystrophin in mice reduces NO-dependent vascular function and vascular density: total recovery after a treatment with the aminoglycoside gentamicin. Arterioscler. Thromb. Vasc. Biol. 2004, 24:671-676.
137. Welch E.M., et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007, 447:87-91.
138. Allamand V., et al. Drug-induced readthrough of premature stop codons leads to the stabilization of laminin alpha2 chain mRNA in CMD myotubes. J. Gene Med. 2008, 10:217-224.
139. Du L., et al. Nonaminoglycoside compounds induce readthrough of nonsense mutations. J. Exp. Med. 2009, 206:2285-2297.
140. Kayali R., et al. Read-through compound 13 restores dystrophin expression and improves muscle function in the mdx mouse model for Duchenne muscular dystrophy. Hum. Mol. Genet. 2012, 21:4007-4020.
141. Lai C.H., et al. Correction of ATM gene function by aminoglycoside-induced read-through of premature termination codons. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:15676-15681.
142. Nakamura K., et al. Functional characterization and targeted correction of ATM mutations identified in Japanese patients with ataxia-telangiectasia. Hum. Mutat. 2012, 33:198-208.
143. Brendel C., et al. Suppression of nonsense mutations in Rett syndrome by aminoglycoside antibiotics. Pediatr. Res. 2009, 65:520-523.
144. Popescu A.C., et al. Aminoglycoside-mediated partial suppression of MECP2 nonsense mutations responsible for Rett syndrome in vitro. J. Neurosci. Res. 2010, 88:2316-2324.
145. Brendel C., et al. Readthrough of nonsense mutations in Rett syndrome: evaluation of novel aminoglycosides and generation of a new mouse model. J. Mol. Med. (Berl) 2011, 89:389-398.
146. Vecsler M., et al. Ex vivo treatment with a novel synthetic aminoglycoside NB54 in primary fibroblasts from Rett syndrome patients suppresses MECP2 nonsense mutations. PLoS ONE 2011, 6:e20733.
147. Rebibo-Sabbah A., et al. In vitro and ex vivo suppression by aminoglycosides of PCDH15 nonsense mutations underlying type 1 Usher syndrome. Hum. Genet. 2007, 122:373-381.
148. Nudelman I., et al. Redesign of aminoglycosides for treatment of human genetic diseases caused by premature stop mutations. Bioorg. Med. Chem. Lett. 2006, 16:6310-6315.
149. Goldmann T., et al. PTC124-mediated translational readthrough of a nonsense mutation causing Usher syndrome type 1C. Hum. Gene. Ther. 2011, 22:537-547.
150. Keeling K.M., et al. Gentamicin-mediated suppression of Hurler syndrome stop mutations restores a low level of alpha-l-iduronidase activity and reduces lysosomal glycosaminoglycan accumulation. Hum. Mol. Genet. 2001, 10:291-299.
151. Keeling K.M., Bedwell D.M. Clinically relevant aminoglycosides can suppress disease-associated premature stop mutations in the IDUA and P53 cDNAs in a mammalian translation system. J. Mol. Med. (Berl) 2002, 80:367-376.
152. Hein L.K., et al. Alpha-l-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients. J. Mol. Biol. 2004, 338:453-462.
153. Brooks D.A., Muller V.J., Hopwood J.J. Stop-codon read-through for patients affected by a lysosomal storage disorder. Trends Mol. Med. 2006, 12:367-373.
154. Wang D., et al. The designer aminoglycoside NB84 significantly reduces glycosaminoglycan accumulation associated with MPS I-H in the Idua-W392X mouse. Mol. Genet. Metab. 2012, 105:116-125.
155. Bartolomeo R., et al. Pharmacological read-through of nonsense ARSB mutations as a potential therapeutic approach for mucopolysaccharidosis VI. J. Inherit. Metab. Dis. 2013, 36:363-371.
156. Tan L., et al. PTC124 improves readthrough and increases enzymatic activity of the CPT1A R160X nonsense mutation. J. Inherit. Metab. Dis. 2011, 34:443-447.
157. James P.D., et al. Aminoglycoside suppression of nonsense mutations in severe hemophilia. Blood 2005, 106:3043-3048.
158. Yang C., et al. A mouse model for nonsense mutation bypass therapy shows a dramatic multiday response to geneticin. Proc. Natl. Acad. Sci. U.S.A. 2007, 104:15394-15399.
159. Buck N.E., et al. Stop codon read-through of a methylmalonic aciduria mutation. Mol. Genet. Metab. 2009, 97:244-249.
160. Sleat D.E., et al. Aminoglycoside-mediated suppression of nonsense mutations in late infantile neuronal ceroid lipofuscinosis. Eur. J. Paediatr. Neurol. 2001, 5(Suppl A):57-62.
161. Sarkar C., Zhang Z., Mukherjee A.B. Stop codon read-through with PTC124 induces palmitoyl-protein thioesterase-1 activity, reduces thioester load and suppresses apoptosis in cultured cells from INCL patients. Mol. Genet. Metab. 2011, 104:338-345.
162. Wolstencroft E.C., et al. A non-sequence-specific requirement for SMN protein activity: the role of aminoglycosides in inducing elevated SMN protein levels. Hum. Mol. Genet. 2005, 14:1199-1210.
163. Allen L.A., Raetz C.R. Partial phenotypic suppression of a peroxisome-deficient animal cell mutant treated with aminoglycoside G418. J. Biol. Chem. 1992, 267:13191-13199.
164. Dranchak P.K., et al. Nonsense suppressor therapies rescue peroxisome lipid metabolism and assembly in cells from patients with specific PEX gene mutations. J. Cell Biochem. 2011, 112:1250-1258.
165. Brumm H., et al. Rescue of melanocortin 4 receptor (MC4R) nonsense mutations by aminoglycoside-mediated read-through. Obesity (Silver Spring) 2012, 20:1074-1081.
166. Fuchshuber-Moraes M., et al. Aminoglycoside-induced suppression of CYP2C19*3 premature stop codon. Pharmacogenet. Genomics 2011, 21:694-700.
167. Sun J., et al. Relationships among stop codon usage bias, its context, isochores, and gene expression level in various eukaryotes. J. Mol. Evol. 2005, 61:437-444.
168. Tate W.P., et al. Translational termination efficiency in both bacteria and mammals is regulated by the base following the stop codon. Biochem. Cell Biol. 1995, 73:1095-1103.
169. Tork S., et al. The major 5' determinant in stop codon read-through involves two adjacent adenines. Nucl. Acids Res. 2004, 32:415-421.
170. Malik V., et al. Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann. Neurol. 2010, 67:771-780.
171. Du M., et al. Poly-l-aspartic acid enhances and prolongs gentamicin-mediated suppression of the CFTR-G542X mutation in a cystic fibrosis mouse model. J. Biol. Chem. 2009, 284:6885-6892.
172. Durand S., et al. Inhibition of nonsense-mediated mRNA decay (NMD) by a new chemical molecule reveals the dynamic of NMD factors in P-bodies. J. Cell Biol. 2007, 178:1145-1160.
173. Keeling K.M., et al. Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression. PLoS ONE 2013, 8:e60478.